BridgePoint Medical Closes $9.1 Million Series C Financing

MINNEAPOLIS, March 10, 2011 - BridgePoint Medical, Inc., a private company developing innovative and
proprietary technology in the field of interventional cardiology for crossing
coronary and peripheral chronic total occlusions (CTO), announced today that
it has completed its third round of financing earlier this year, totaling
$9.1 million. The round was lead by a new strategic investor and joined by
existing investors New Enterprise Associates, Polaris Venture Partners,
Foundation Medical Partners and Michael Berman.

Interventional cardiologists are currently unable to broadly treat
patients with chronic total occlusions which comprise approximately one third
of all patients with coronary artery disease and approximately one half of
patients with peripheral artery disease. For these patients, the common
alternative is bypass surgery or palliative care. In order to treat a CTO
patient with minimally invasive therapy, a physician must first successfully
cross the blockage and place a guidewire beyond the occlusion. BridgePoint
Medical's CrossBoss(TM) Catheter and Stingray(TM) System are uniquely
designed to facilitate guidewire placement and subsequent dilatation balloon
or Drug Eluting Stent (DES) placement in this challenging anatomy.

"The inability to successfully deliver therapeutic tools severely limits
patient options for CTO treatment today. We believe that BridgePoint Medical
has the technology and the team to address this challenge and the potential
to reduce the need for highly invasive and expensive bypass surgery," said
Andrew Firlik, General Partner, Foundation Medical Partners.

In September, 2010 the company completed the U.S. Facilitated Antegrade
Steering Technique in Chronic Total Occlusions (FAST-CTOs) Study. The study
evaluated the ability of the CrossBoss(TM) Catheter and Stingray(TM) System
to successfully and safely facilitate placement of a guidewire beyond a CTO
in the vessel true lumen in cases that were otherwise refractory to treatment
with a conventional guidewire. One hundred forty-seven patients were enrolled
at 20 sites. The company has filed a 510(k) with the FDA requesting market
clearance for the indication of coronary CTO treatments in the U.S.

The Series C financing will be used to enable marketing and sales efforts
for BridgePoint's CrossBoss(TM) Catheter and Stingray(TM) System in the
United States, Europe and Japan through the use of distributors and direct
sales. Additionally, BridgePoint Medical will be initiating a U.S. IDE study
of the technologies in peripheral artery disease in the first half of 2011.

"The addition of a new investor combined with the continuing commitment
of our present investors is a testament to the significant progress we have
made in the development and investigation of our CrossBoss(TM) Catheter and
Stingray(TM) System. This funding will enable us to accelerate growth through
initiation of commercialization activities globally," stated Michael Berman
of Berman Medical and Chairman of the BridgePoint Board of directors.

About BridgePoint Medical

BridgePoint Medical, Inc. is a privately held company established in 2006
to design, develop and commercialize new technologies and techniques to treat
challenging coronary and peripheral artery disease.

BridgePoint Medical, Inc., +1-763-225-8500